AIP
ABMD

Almanack Investment Partners’s Abiomed Inc ABMD Stock Holding History

Almanack Investment Partners’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-28
Closed -$7K – 855
2022
Q3 		$7K Buy
+28
New +$7.56K ﹤0.01% 546

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $537M AUM 18.24% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Almanack Investment Partners's ABMD Position: Q4 2022 in Review

Almanack Investment Partners sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 28 shares — an estimated $7K sold.

Almanack Investment Partners first reported a position in ABMD in Q3 2022 and held it in 1 quarter. The position peaked at $7K in Q3 2022. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Almanack Investment Partners reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Almanack Investment Partners sold 28 Abiomed Inc shares in Q4 2022, an estimated $7K.
  • Almanack Investment Partners first reported a position in Abiomed Inc in Q3 2022 and held it in 1 quarter.
  • Almanack Investment Partners's Abiomed Inc position peaked at $7K in Q3 2022.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Almanack Investment Partners's 13F filing for Q4 2022, filed 9 Feb 2023.